Stanford Peng is a member of Gentibio scientific advisory board. He is President and Head of Research and Development at Alpine Immune Sciences (NASDAQ: ALPN) and a practicing rheumatologist. Before joining Alpine Immune Sciences, Stanford was Chief Medical Officer at Stemcentrx, Inc., until its acquisition by AbbVie and previously held various positions at Seattle Genetics and Roche, as well as the Benaroya Research Institute and Washington University in St. Louis. Dr. Peng received a B.A. and B.S. in Music and Biological Sciences from Stanford University, as well as an M.D. and Ph.D. in Biology from Yale University. He conducted his residency in internal medicine at the University of Pennsylvania and was a Clinical and Research Fellow in rheumatology at Brigham & Women’s Hospital.
Amy Jennings is a member of GentiBio Scientific Advisory Board. Amy is the Founder and Principal Regulatory Consultant at RegPath LLC, which provides product development and regulatory support to small biotechnology companies. Prior to founding RegPath, Amy was the SVP, Head of Regulatory Affairs at Casebia Therapeutics and served as the cross-functional Project Lead for the autoimmune/tolerance edited T regulatory cell program. Prior to Casebia, She was the SVP, Head of Regulatory at Achillion Pharmaceuticals and, earlier, served as Sanofi’s associate vice president for global regulatory affairs in the company’s North American diabetes program. Before Sanofi, Amy held positions of increasing responsibility at Bristol-Myers Squibb. Dr. Jennings received her B.Sc. in Chemistry from the University of Wisconsin-Madison, her Ph.D. in Biochemistry from The Ohio State University, and was a post-doctoral fellow at the Harvard-affiliated Joslin Diabetes Center.
David Rawlings is Scientific Co-founder, Senior Scientific Advisor for GentiBio and member of its Scientific Advisory Board. , He is also the Director of the Center for Immunity and Immunotherapies at Seattle Children’s Research Institute and Chief of the Division of Immunology overseeing the immunodeficiency clinical program at Seattle Children’s Hospital. David is a Professor of Pediatrics and Immunology at the University of Washington and previously held faculty appointments at UCLA. He has received numerous awards including the Seattle Children’s Guild Association Endowed Chair in Pediatric Immunology, Tom Hansen Investigator in Pediatric Innovation Endowment, and election to the American Society for Clinical Investigation and Association of American Physicians. David received a B.S. in Biological Sciences, Magna Cum Laude from Davidson College and received his M.D. from the University of North Carolina.
Hadas Weinstein-Marom is Scientific Co-founder of GentiBio and member of its scientific advisory board. She is a senior scientist at the Immunology Laboratory of MIGAL – Galilee Research Institute and a lecturer in the Biotechnology Department at Tel-Hai College. In the field of immuno-gene therapy of cancer, her research focuses on improving the selectivity and safety of adoptive T cell therapy and on enhancing the functional properties and survival of antitumor T cells. In the field of inflammatory diseases, her research focus is on genetically engineering regulatory T cells as a new tool for immunotherapy. Hadas received her B.Sc. in life sciences, M.Sc. in biotechnology-immunology, and Ph.D. in cancer immunotherapy, all from the Hebrew University of Jerusalem. She conducted her postdoctoral research with the Ella Lemelbaum Institute for Immuno-Oncology at the Sheba Medical Center and Tel Aviv University.
Gideon (Gidi) Gross is Scientific Co-founder of GentiBio and member of its scientific advisory board. Gidi is Head of the Immunology Laboratory at MIGAL – Galilee Research Institute in Kiryat Shmona, Israel, and is a senior faculty member at the nearby Tel-Hai College. His research focuses on the development of new gene-based approaches for immunotherapy of multiple diseases. Gidi completed his undergraduate studies at the Open University and obtained his M.Sc. and Ph.D. degrees from the Weizmann Institute of Science in Rehovot, Israel. During his Ph.D. research with Prof. Z. Eshhar, Dr. Gross developed chimeric antigen receptors, laying the ground for CAR-T cell therapy. He conducted his postdoctoral research at the National Cancer Institute in Bethesda, MD, and then at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge, UK.
Andy Scharenberg is Scientific Co-founder of GentiBio and Chair of its Scientific Advisory Board In addition, Andy is Co-founder and CEO of Umoja Biopharma, an MPM Capital portfolio company, and an executive partner at MPM Capital. He is recently retired from prior positions as Attending Physician at Seattle Children’s Hospital and Professor of Pediatrics and Adjunct Professor of Immunology at the University of Washington School of Medicine in Seattle. Prior to founding Umoja, Andy co-directed the Program in Cell and Gene Therapy at Seattle Children’s Research Institute, working to translate cell and gene therapies for the treatment of inherited immunologic and blood diseases. Immeditaley prior to Umoja, he was chief scientific officer (CSO) of Casebia Therapeutics. Previously, he was the CSO of Cellectis Therapeutics, where he initiated the development of an allogeneic CAR T cell platform that is the foundational technology for Allogene, and co-founded Pregenen Inc., a gene editing and cell-signaling technology company that was acquired by bluebird bio in 2014. Andrew earned his M.D. from the University of North Carolina School of Medicine. He completed his residency at the University of North Carolina Children’s Hospital and his fellowship in immunology at NIH and at the Division of Experimental Pathology, Beth Israel Hospital.
Jane Buckner is Scientific Co-founder of GentiBio and member of its scientific advisory board. . Jane is the President and Director of the Translational Research Core at the Benaroya Research Institute at Virginia Mason (BRI), Affiliate Professor of Immunology at the University of Washington, Affiliate Professor of Medicine, Division of Rheumatology also at the University of Washington, and a Partner at the Allen Institute for Immunology. She is a practicing rheumatologist at Virginia Mason Medical Center. Jane received her bachelor’s degree in chemistry from Carleton College and her medical degree from Johns Hopkins School of Medicine. She completed her residency in Internal Medicine at the University of Minnesota and was a fellow in rheumatology at the University of Washington.